Saridegib, also known as IPI-926, is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including...
4 KB (193 words) - 00:48, 7 May 2023
accepting group is more impactful, having both makes for stronger binding. Saridegib (also known as IPI-926), a semisynthetic analog of cyclopamine Vismodegib...
16 KB (1,441 words) - 13:23, 1 June 2024
Other SMO inhibitors currently under clinical trial include IPI-926 (saridegib), BMS-833923 / XL139 (developed by Bristol-Myers Squibb / Exelexis), PF-04449913...
27 KB (3,866 words) - 12:49, 22 August 2024